|

LMP744 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Institute of Neurological Disorders and Stroke (NINDS)1

Indications

  • Recurrent Glioma (Glioblastoma Multiforme)1
  • Grade IV Astrocytoma1
  • Glioblastomas1
  • Recurring Glioblastoma1
  • Brain and Central Nervous System Tumors1

Bethesda, Maryland1 trial

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.